Pancreatic Elastase-1 Quick Test for rapid assessment of pancreatic status in cystic fibrosis patients

Walkowiak, Jarosław; Glapa, Aleksandra; Nowak, Jan Krzysztof; Bober, L.; Rohovyk, Nataliya; Wenska-Chyży, Ewa; Sobkowiak, Paulina; Lisowska, Aleksandra

doi:10.1016/j.jcf.2016.05.009

Cited by 12 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a new rapid FE-1 test has been developed that allows for results to be obtained within minutes. This rapid test was compared with the classical FE-1 ELISA, with the following sensitivities and specificities in the studied groups: 92.8 and 96.6% in all subjects, 90.5 and 100% in Dig Dis Sci screening non-CF samples, and 92.8 and 90.5% in CF patients [32].…”

Section: The Fecal Elastase-1 Testmentioning

confidence: 99%

Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test

et al. 2017

View full text Add to dashboard Cite

The early diagnosis of pancreatic exocrine insufficiency (PEI) is hindered because many of the functional diagnostic techniques used are expensive and require specialized facilities, which prevent their widespread availability. We have reviewed current evidence in order to compare the utility of these functional diagnostic techniques with the fecal elastase-1 (FE-1) test in the following three scenarios: screening for PEI in patients presenting with symptoms suggestive of pancreatic disease, such as abdominal pain or diarrhea; determining the presence of PEI in patients with an established diagnosis of pancreatic disease, such as chronic pancreatitis or cystic fibrosis; determining exocrine status in disorders not commonly tested for PEI, but which have a known association with this disorder. Evidence suggests the FE-1 test is reliable for the evaluation of pancreatic function in many pancreatic and non-pancreatic disorders. It is non-invasive, is less time-consuming, and is unaffected by pancreatic enzyme replacement therapy. Although it cannot be considered the gold-standard method for the functional diagnosis of PEI, the advantages of the FE-1 test make it a very appropriate test for screening patients who may be at risk of this disorder.

show abstract

Section: The Fecal Elastase-1 Testmentioning

confidence: 99%

Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The diagnosis of CF was done according to the international criteria (Farrell et al, 2017 ). Pancreatic sufficiency in patients with CF was defined on the basis of two values of faecal pancreatic elastase > 200 mg/g measured in subjects free from acute gastrointestinal events (Walkowiak et al, 2016 ) or on the basis of normal 72-h fecal fat balance (Walkowiak et al, 2008 ). Recurrent pancreatitis was diagnosed in patients that had at least two episodes of acute pancreatitis (at a distance of at least six months after the resolution of the previous episode) each one with abdominal pain (once excluded other causes) in association with the increase of serum lipase (at least 2X the upper reference limit) and/or imaging evidence (e.g., pancreatic edema, hemorrhage or necrosis) (Morinville et al, 2012 ; Kumar et al, 2016 ).…”

Section: Methodsmentioning

confidence: 99%

Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with Cystic Fibrosis

Sofia

Surace

Terlizzi

et al. 2018

Mol Med

View full text Add to dashboard Cite

BackgroundRecurrent (RP) and chronic pancreatitis (CP) may complicate Cystic Fibrosis (CF). It is still unknown if mutations in genes involved in the intrapancreatic activation of trypsin (IPAT) or in the pancreatic secretion pathway (PSP) may enhance the risk for RP/CP in patients with CF.MethodsWe enrolled: 48 patients affected by CF complicated by RP/CP and, as controls 35 patients with CF without pancreatitis and 80 unrelated healthy subjects. We tested a panel of 8 genes involved in the IPAT, i.e. PRSS1, PRSS2, SPINK1, CTRC, CASR, CFTR, CTSB and KRT8 and 23 additional genes implicated in the PSP.ResultsWe found 14/48 patients (29.2%) with mutations in genes involved in IPAT in the group of CF patients with RP/CP, while mutations in such genes were found in 2/35 (5.7%) patients with CF without pancreatitis and in 3/80 (3.8%) healthy subjects (p < 0.001). Thus, we found mutations in 12 genes of the PSP in 11/48 (22.9%) patients with CF and RP/CP. Overall, 19/48 (39.6%) patients with CF and RP/CP showed one or more mutations in the genes involved in the IPAT and in the PSP while such figure was 4/35 (11.4%) for patients with CF without pancreatitis and 11/80 (13.7%) for healthy controls (p < 0.001).ConclusionsThe trans-heterozygous association between CFTR mutations in genes involved in the pathways of pancreatic enzyme activation and the pancreatic secretion may be risk factors for the development of recurrent or chronic pancreatitis in patients with CF.Electronic supplementary materialThe online version of this article (10.1186/s10020-018-0041-6) contains supplementary material, which is available to authorized users.

show abstract

“…The presence of homozygous or compound heterozygous class I or II mutations in CF patients was considered a severe genotype (Table S1 (Supplementary Materials)) [12]. Patients were divided into pancreatic sufficient and insufficient on the basis of elastase-1 concentration in stools (ELISA; Schebo Biotech, Giessen, Germany) [17][18][19]. Patient's FEV 1 % was collected from the medical records (value closest to blood collection).…”

Section: Patientsmentioning

confidence: 99%

Leukocyte Telomere Length Is Not Reduced in Children and Adults with Cystic Fibrosis but Associates with Clinical Characteristics—A Cross-Sectional Study

Glapa-Nowak

Mutt

Lisowska

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

We hypothezied that telomere length is considerably altered in cystic fibrosis (CF) patients compared to healthy subjects (HS), and that leukocyte telomere length variation reflects the severity of CF. Relative telomere length (RTL) was assessed by qPCR in 70 children aged 5–10 (34 CF; 36 HS) and 114 adults aged 18–45 (53 CF; 61 HS). Telomere length was similar in CF and HS (median (interquartile range): 0.799 (0.686–0.950) vs. 0.831 (0.707–0.986); p = 0.5283) both in children and adults. In adults, women had longer telomeres than men (0.805 (0.715–0.931) vs. 0.703 (0.574–0.790); p = 0.0002). Patients treated with inhaled corticosteroids had a shorter RTL compared to those without steroid therapy (0.765 (0.664–0.910) vs. 0.943 (0.813–1.191); p = 0.0007) and this finding remained significant after adjusting for gender, age, BMI, and child/adult status (p = 0.0003). Shorter telomeres were independently associated with the presence of comorbidities (0.763 (0.643–0.905) vs. 0.950 (0.783–1.130); p = 0.0006) and antibiotic treatment at the moment of blood sampling (0.762 (0.648–0.908) vs. 0.832 (0.748–1.129); p = 0.0172). RTL correlated with number of multiple-day hospitalizations (rho = −0.251; p = 0.0239), as well as number of hospitalization days (rho = −0.279; p = 0.0113). Leukocyte RTL in children and adults with CF was not shorter than in healthy controls, and did not seem to have any potential as a predictor of CF survival. However, it inversely associated with the investigated clinical characteristics.

show abstract

Pancreatic Elastase-1 Quick Test for rapid assessment of pancreatic status in cystic fibrosis patients

Abstract: Pancreatic Elastase-1 Quick Test™ proves to be a rapid and reliable option to qualitatively evaluate pancreatic function for diagnostic purposes in a clinical setting of CF care.

Cited by 12 publications

References 17 publications

Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test

Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test

Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with Cystic Fibrosis

Leukocyte Telomere Length Is Not Reduced in Children and Adults with Cystic Fibrosis but Associates with Clinical Characteristics—A Cross-Sectional Study

Contact Info

Product

Resources

About